Invasight
accelerates drug discovery and enables the design of specific protein-protein interaction antagonists (PPIAs) against non-traditional intracellular protein targets, which cause cancer cell invasion
Invasight has raised €4.3M across 1 funding round from 2 investors, most recently a Seed round in Jun 2022. Based in Zurich, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Zurich, Switzerlandinvasight.com ↗
Total raised
€4.3M
€4,317,375
Funding rounds
1
Investors
2
distinct backers
Active since
2022-06
latest 2022-06
Funding by year
EUR raised per yearInvasight — funding by year — interactive chart.
Data table
| Invasight — funding by year | |
|---|---|
| 2022 | €4.3M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Seed
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-06-07 | Seed | €4.3M | JFG Life Sciences Foundation,OCCIDENT | View deal → |
Investors
2Related news
- Invasight closes CHF 4.5 million seed round to fight invasive cancersstartupticker.ch · 2022-06
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData